

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
森実千種、奥坂拓志.	胆道がんでの臨床試験デザイン.		抗がん剤の開発戦略と承認申請のポイント.	技術情報協会.	東京	2011	36-47
森実千種、奥坂拓志.	6. 胆道がん	古瀬純司編集.	消化器がん化学療法.	中外医学社.	東京	2011	172-181
森実千種、奥坂拓志.	胆嚢・胆管がん.		各疾患領域の治療の現状とメディカルニーズのDATE BOOK.	技術情報協会	東京	2010	49-56
古瀬純司.	VI. 肝細胞癌/胆道癌/膵癌. 肝・胆道・膵癌化学療法の最近の動向.	有吉寛総監修	エビデンスに基づいた癌化学療法ハンドブック2012.	メディカルレビュー社	東京	2012	262-273
鈴木英一郎, 古瀬純司.	VI. 肝細胞癌/胆道癌/膵癌. 胆道癌. A. 保険医療で可能なregimen. 1st line. GC (GEM+CDDP) 療法.	有吉寛総監修	エビデンスに基づいた癌化学療法ハンドブック2012.	メディカルレビュー社	東京	2012	278-279
鈴木英一郎, 古瀬純司	VI. 肝細胞癌/胆道癌/膵癌. 胆道癌. A. 保険医療で可能なregimen. 1st line. GEM.	有吉寛総監修	エビデンスに基づいた癌化学療法ハンドブック2012.	メディカルレビュー社	東京	2012	280-281
鈴木英一郎, 古瀬純司.	VI. 肝細胞癌/胆道癌/膵癌. 胆道癌. A. 保険医療で可能なregimen. S-1.	有吉寛総監修	エビデンスに基づいた癌化学療法ハンドブック2012.	メディカルレビュー社	東京	2012	282-283
古瀬純司.	胆道がん.	佐藤隆美, 藤原康弘, 古瀬純司, 大山優編.	What's New in Oncology がん治療エッセンシャルガイド改訂2版.	南山堂	東京	2012	415-425

書籍

著者氏名	論文タイトル	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
土岐真朗, 山口康晴, 高橋真一, 古瀬純司.	閉塞性黄疸より診断に至った胆管癌.	中川和彦, 伊藤良則, 古瀬純司, 朴成和, 直江知樹編	症例から学ぶメデイカルオンコロジー.	医薬ジャーナル	大阪	2011	236-245
古瀬純司.	抗癌剤【肝胆膵】.	渡邊昌彦, 國土典広, 土岐祐一郎監修.	消化器外科レビュー2010.	総合医学社	東京	2010	199-204
古瀬純司, 鈴木英一郎, 長島文夫.	膵・胆道がんに対する薬物療法.	市倉隆, 市川度編.	消化器がん薬物療法2010.	日本メディカルセンター	東京	2010	208-215
鈴木英一郎, 古瀬純司.	切除不能進行胆道がんの標準治療はなにか? GEM と S-1 をどう使うか? 胆道がん. 肝・胆・膵のがん.	大津敦, 古瀬純司, 中川和彦, 徳田裕, 南博信, 畠清彦, 田村和夫編.	EBMがん化学療法・分子標的治療法.	中外医学社	東京	2010	130-133
浅木彰則, 井口東郎.	8章 胆道がんにおける新しい予後予測因子とその臨床応用及び求められる治療薬像.	佐藤章弘 編	新しいバイオマーカー/予測因子による個別化医療時代に求められる抗がん剤開発	(株)技術情報協会	東京	2011	185-192

雑誌

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
<u>Furuse J, Ishii H, Okusaka T.</u>	The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): History and Future Direction.	Jpn J Clin Oncol	43(1)	2-7	2013
<u>Okusaka T, Ueno M, Sato T, Heike Y.</u>	Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).	J Hepatobiliary Pancreat Sci	19(4)	314-318	2012
<u>Fukutomi A, Furuse J, Okusaka T, Miyazaki M, Taketsuna M, Koshiji M, Nimura Y.</u>	Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study.	HPB	14(4)	221-227	2012
Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Ueno H, Kondo S, Morizane C, <u>Ikeda M, Okusaka T, Takaue Y, Heike Y.</u>	Phase 1 trial of wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.	J Immunother	34(1)	92-99	2011
<u>Furuse J, Okusaka T.</u>	Review: Targeted therapy for biliary tract cancer.	Cancers	3(2)	2243-2254	2011
<u>Furuse J, Okusaka T, Bridgewater J, Taketsuna M, Wasan H, Koshiji M, Valle J.</u>	Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer.	Critical Reviews in Oncol Hematol	80(1)	31-39	2011

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
<u>Okusaka T</u> , Nakachi K, <u>Fukutomi A</u> , Mizuno N, <u>Ohkawa S</u> , Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, <u>Furuse J</u> , Miyazaki M, Nimura Y.	Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in Japan.	Br J Cancer	103(4)	469-474	2010
Iwasa S, Morizane C, <u>Okusaka T</u> , Ueno H, <u>Ikeda M</u> , Kondo S, Tanaka T, Nakachi K, Mitusnaga S, Kojima Y, Hagihara A, Hiraoka N.	Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.	Jpn J Clin Oncol	40(4)	313-318	2010
Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, <u>Okusaka T</u> , Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.	Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.	Cancer Sci	101(4)	882-888	2010
Sugiyama E, Kaniwa N, Kim S-R, Hasegawa R, Saito Y, Ueno H, <u>Okusaka T</u> , <u>Ikeda M</u> , Morizane C, Kondo S, Yamamoto N, Tamura T, <u>Furuse J</u> , <u>Ishii H</u> , Yoshida T, Saijo N, Swada,	Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients.	J Clin Pharmacokinet	49(8)	549-558	2010

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
Takashima A, Morizane C, <u>Ishii H</u> , Nakamura K, Fukuda H, <u>Okusaka T</u> , <u>Furuse J</u> .	Randomized phase II study of gemcitabine plus s-1 combination therapy vs. S-1 in advanced biliary tract cancer. Japan Clinical Oncology Group Study (JCOG0805).	Jpn J Clin Oncol	40(12)	1189-1191	2010
Soeda A, Morita-Hoshi Y, Kaida M, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, <u>Ikeda M</u> , <u>Okusaka T</u> , Heike Y.	Long-term administration of wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.	Jpn J Clin Oncol	40(12)	1184-1188	2010
Suzuki E, <u>Furuse J</u> , <u>Ikeda M</u> , <u>Okusaka T</u> , Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A.	Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.	Oncology	79(1-2)	39-45	2010
Koizumi M, <u>Sata N</u> , Kasahara N, Morishima K, Kaneda Y, Fujiwara T, Ota M, Hyodo M, Yasuda Y.	Carcinoid tumor of the gall bladder: Report of two cases.	Clin J Gastroenterol	4	323-330	2011
Hatanaka H, Takada S, Tsukui M, Choi YL, Kurashina K, Soda M, Yamashita Y, Haruta H, Hamada T, Tamada K, Hosoya Y, <u>Sata N</u> , Nagai H, Yasuda Y, Sugano K, Mano H.	Identification of the transforming activity of Indian hedgehog by retroviral expression screening.	Cancer Sci	101(1)	60-64	2010

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
Hatanaka H, Tsukui M, Takada S, Kurashina K, Choi YL, Soda M, Yamashita Y, Haruta H, Hamada T, Ueno T, Tamada K, Hosoya Y, Sata N, Yasuda Y, Nagai H, Sugano K, Mano H.	Identification of transforming activity of free fatty acid receptor 2 by retroviral expression screening.	Cancer Sci	101(1)	54-59	2010
Inaba Y, Arai Y, Yamamura H, Sato Y, Najima M, Aramaki T, Sone M, Kumada T, Tanigawa N, Anai H, Yoshioka T, Ikeda M ; for Japan Interventional Radiology in Oncology Study Group (JIVROSG).	Phase I/II Study of Hepatic Arterial Infusion Chemotherapy With Gemcitabine in Patients With Unresectable Intrahepatic Cholangiocarcinoma (JIVROSG-0301).	Am J Clin Oncol	34(1)	58-62	2011
Yukisawa S, Ishii H, Matsuyama M, Kuraoka K, Takano K, Kamei A, Ozaka M.	Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older.	Jpn J Clin Oncol	41(1)	76-80	2011
Takashima A, Morizane C, Ishii H, Nakamura K, Fukuda H, Okusaka T, Furuse J.	Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805)	Jpn J Clin Oncol	40(12)	1189-91	2010
Furuse J, Kasuga A, Takasu A, Kitamura H, Nagashima F.	Role of chemotherapy in treatments for biliary tract cancer.	J Hepatobiliary Pancreat Sci.	19(4)	337-41	2012
Furuse J, Nagashima F.	Inhibitor of MEK1/2, selumetinib, for biliary tract cancer.	Expert Rev Gastroenterol Hepatol.	5(5):	579-581	2011
Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R, Yamamoto N, Morinaga S.	A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.	Jpn J Clin Oncol	42(9)	800-806	2012

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H, Bhatia V, Shimizu Y.	Endoscopic ultrasound-guided choledochoduodenostomy for malignant lower biliary tract obstruction.	Gastrointest Endosc Clin N Am.	22(2)	259-269	2012
Hijioka S, Hara K, Mizuno N, Imaoka H, Ogura T, Haba S, Mekky MA, Bhatia V, Hosoda W, Yatabe Y, Shimizu Y, Niwa Y, Tajika M, Kondo S, Tanaka T, Tamada K, Yamao K.	Diagnostic yield of endoscopic retrograde cholangiography and of EUS-guided fine needle aspiration sampling in gallbladder carcinomas.	J Hepatobiliary Pancreat Sci.	19(6)	650-655	2012
Hara K, Bhatia V, Hijioka S, Mizuno N, Yamao K.	A convex EUS is useful to diagnose vascular invasion of cancer, especially hepatic hilus cancer.	Dig Endosc.	23 (Suppl 1)	26-28	2011,
Hara K, Yamao K, Niwa Y, Sawaki A, Mizuno N, Hijioka S, Tajika M, Kawai H, Kondo S, Kobayashi Y, Matumoto K, Bhatia V, Shimizu Y, Ito A, Hirooka Y, Goto H.	Prospective Clinical Study of EUS-Guided Choledochoduodenostomy for Malignant Lower Biliary Tract Obstruction.	Am J Gastroenterol.	106(7)	1239-1245	2011,
Hijioka S, Mekky M A, Bhatia V, Sawaki A, Mizuno N, Hara K, Hosoda W, Shimizu Y, Tamada K, Niwa Y, Yamao K.	Can EUS-guided FNA distinguish between gallbladder cancer and xanthogranulomatous cholecystitis?	Gastrointest Endosc.	72(3)	622-627	2010
Hara K, Yamao K, Mizuno N, Sawaki A, Takagi T, Bhatia V.	Endoscopic ultrasound-guided choledochoduodenostomy.	Dig Endosc	22(2)	147-150	2010

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
坂本康成、上野秀樹、 <u>奥坂拓志</u> 。	膵胆道癌化学療法の最前線。胆・膵疾患診療の最前線・治療／最新の治療戦略とその成果－病診連携のために－	Medical Practice	29(1)	140-144	2012
<u>奥坂拓志</u> 、 <u>古瀬純司</u> 、 <u>宮崎 勝</u> 、 <u>二村雄次</u> 。	見直される胆道がん診療の新展開。V. 化学療法 1. 進行切除不能胆道がんに対するゲムシタビン＋シスプラチン併用療法～我が国で実施されたランダム化第Ⅱ相試験の成績を中心に～	肝胆膵	62(6)	1131-1139	2011
<u>奥坂拓志</u> 。	わが国における国際共同臨床試験（企業治験および研究者主導試験）の現状と問題点4）肝胆膵がん。特集国際共同臨床試験の現状と問題点。	腫瘍内科	7(3)	263-268	2011
<u>奥坂拓志</u> 。	IV. 薬物療法の進歩。Liver, Pancreas, Biliary Tract Cancer. 肝・胆・膵 癌。膵神経内分泌腫瘍2011 Update.	癌と化学療法	38(10)	1613-1618	2011
<u>奥坂拓志</u> 。	膵がん・胆道がんの治療－ゲムシタビンから分子標的治療薬まで。化学療法アップデート。	日経メディカルCancer Research	25	39-43	2011
<u>池田公史</u> 、 <u>仲地耕平</u> 、 <u>光永修一</u> 、 <u>上野秀樹</u> 、 <u>森実千種</u> 、 <u>近藤俊輔</u> 、 <u>奥坂拓志</u> 。	全身化学療法の進歩。	消化器外科	34(7)	1069-1076	2011
<u>奥坂拓志</u> 、 <u>平家勇司</u> 。	癌免疫療法の臨床試験手法	Medical Science Digest	36(4)	18-21	2010
<u>丹尾幸樹</u> 、 <u>上野秀樹</u> 、 <u>奥坂拓志</u> 。	12 ゲムシタビン療法。2部1章 従来型抗がん剤とレジメンをもっと知ろう！消化器がんによく使われるレジメン	消化器外科 NURSING 2010	臨時増刊	62-63	2010
<u>堀之内秀仁</u> 、 <u>奥坂拓志</u> 。	特集にあたって。特集がん診療の考え方・進め方 患者と向き合うための基礎知識	レジデントノート	12(9)	1488-1490	2010

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
仲地耕平、池田公史、光永修一、上野秀樹、森実千種、近藤俊輔、奥坂拓志.	タルセバにおける開発の状況とその効果予測因子. 特集 肝胆膵腫瘍物治療学の進歩—この30年—. 胆膵分野: IX. 膵・胆道癌抗がん剤: 2. 膵・胆道癌の抗がん剤 (現在未承認中).	肝胆膵	61(6)	1290-1295	2010
金丸理人、小泉大、佐田尚宏.	胆管内に進展し閉塞性黄疸をきたしたポリープ型十二指腸乳頭部癌の1例.	胆道	25	768-773	2011
古瀬純司.	肝・胆道・膵癌の化学療法・分子標的治療.	日本肝胆膵外科学会・学術集会プログラム・抄録集	24	151,	2012
市田隆文, 奥坂拓志, 金井文彦, 古瀬純司.	肝胆膵悪性腫瘍に対する分子標的療法の近未来的展望・肝胆膵悪性腫瘍に対する分子標的療法の近未来的展望.	肝・胆・膵	64(5)	735-750	2012
古瀬純司.	肝・胆・膵腫瘍の薬物療法—最近の進歩. 諸言 肝・胆・膵がんに対する薬物療法の動向.	腫瘍内科	9(6)	635-640	2012
古瀬純司, 森実千種, 古川正幸, 山崎秀哉, 味木徹夫.	胆道癌化学療法はこう変わる, こう変える.	膵・胆道癌 Frontier	2(2)	69-75	2012
古瀬純司.	消化器がん化学療法. 主要レジメン理解&看護ポイント. 胆道がんのレジメン. GEM+CDDP.	消化器外科 Nursing	17(9)	952-955	2012
春日章良, 成毛大輔, 有馬志穂, 北村浩, 高須充子, 長島文夫, 吉田正, 野村久祥, 川上英泰, 臼井浩明, 畔蒜祐一郎, 長澤知徳, 古瀬純司.	胆膵領域におけるDPCと電子カルテ時代に対応したクリニカルパス. 膵胆道癌外来化学療法におけるクリニカルパス.	胆と膵	33(9)	745-751	2012

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
古瀬純司, 成毛大輔, 有馬志穂, 春日章良, 北村浩, 高須充子, 長 島文夫.	臓器別最新データ. 胆道癌 . 胆道癌の非切除・再発例	臨床外科	67(11)	207-213	2012
有馬志穂, 成毛大輔, 春日章良, 北村浩, 高 須充子, 長島文夫, 古 瀬純司.	Liver, Pancreas, Bilia ry Tract Cancer. 肝・胆・ 膵癌—胆道癌治療の新展開 . 切除不能進行胆道がんの 化学療法 of 進歩.	癌と化学療法	39(10)	1490-1493	2012
古瀬純司.	特集 がん医療におけるプ ライマリケア医の役割を考 える. ここまで進歩した外 来がん化学療法. 肝癌・胆 道癌・膵癌.	日本医事新報社	4627	57-60	2012
古瀬純司.	胆嚢・胆管がん. かかりつ け医から専門医への質問.	治療増刊号	93	915-917	2011
古瀬純司, 廣川智, 北 村浩, 長島文夫.	胆道癌化学療法の最新情報	胆と膵	32(4)	277-282	2011
古瀬純司, 北村浩, 廣 川智, 高須充子, 長島 文夫.	進行胆道癌に対するS-1療 法の治療成績.	肝胆膵	62(6)	1140-1145	2011
古瀬純司, 北村浩, 高 須充子, 長島文夫.	胆道がん化学療法と看護の ポイント.	消化器外科 NURSING 2011	秋季増刊	98-108	2011
古瀬純司.	膵・胆道癌.	外来癌化学療法	2(3)	21-25	2011
古瀬純司, 北村浩, 高 須充子, 春日章良, 長 島文夫.	臓器別薬物療法. 8. 胆道 癌 ③進行・再発(切除不 能を含む)治療.	臨床外科	66(11)増 刊号	201-208	2011

発表者氏名	論文タイトル名	発表誌	巻号	ページ	出版年
古瀬純司, 高須充子, 北村浩, 春日章良, 長 島文夫.	肝門部胆管癌. (2)治療 . 化学療法.	臨床消化器内科	26(13)	1761-1767	2011
高須充子, 古瀬純司.	胆道がんの化学療法の適応 と実際.	臨床腫瘍プラク ティス	7(4)	381-384	2011
古瀬純司, 鈴木英一 郎, 廣川智, 北村浩, 長島文夫.	胆管癌に対する化学療法.	日本消化器病学 会雑誌	107 (7)	1102-1108	2010
古瀬純司, 鈴木英一 郎, 廣川智, 北村浩, 長島文夫.	胆膵診療における細胞診・ 生検診断の意義.	胆と膵	31 (9)	809-813	2010
上野誠, 奥坂拓志, 平家勇司, 大川伸 二.	進行胆道癌に対する塩酸 Gemcitabine+WT1ペプチ ドワクチン併用化学免疫 療法.	胆と膵	32 (2)	153-155	2010
谷口浩也, 福富晃.	胆道系、膵臓系腫瘍 Cetu ximab.	肝・胆・膵	64	701-710	2012
福富晃, 朴成和.	胆道癌に対する分子標的治 療の臨床試験の現状と展望 .	胆と膵	31	409-416	2010
中森正二.	膵・胆道癌に対する外科的 治療の現状と問題点.	Approach to Oncology	4	4-6	2011
中森正二, 宮本敦史, 浅岡忠史.	胆道がん手術一切除適応と なるのはどこまでか?	臨床腫瘍プラク ティス	7(4)	370-373	2011
井岡達也, 片山和宏.	肝内胆管癌に対する化学療 法の進歩.	日本消化器病学 会誌	109(11)	1895-1901	2012

厚生労働科学研究費補助金
がん臨床研究事業

切除不能胆道がんに対する治療法の確立に関する研究

平成 22～24 年度 研究成果の刊行物・別刷

研究代表者	奥坂	拓志	
研究分担者	宮川	宏之	
	浜本	康夫	※1
	菱沼	正一	※3
	長瀬	通隆	※2
	佐田	尚宏	※4
	山口	研成	
	山口	武人	
	池田	公史	
	石井	浩	
	古瀬	純司	
	大川	伸一	
	田中	克明	
	朴	成和	※1
	福富	晃	※3
	山雄	健次	
	中森	正二	
	井岡	達也	※2
	片山	和宏	※4
	井口	東郎	
	杉本	理恵	
	伊藤	鉄英	

※1 ; 期間 : 平成 22 年度

※2 ; 期間 : 平成 22～23 年度

※3 ; 期間 : 平成 23～24 年度

※4 ; 期間 : 平成 24 年度

Review Article: Study Group

The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): History and Future Direction

Junji Furuse^{1,*}, Hiroshi Ishii² and Takuji Okusaka³

¹Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, ²Gastroenterology Center, Cancer Institute Hospital and ³Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan

*For reprints and all correspondence: Junji Furuse, Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo 181-8611, Japan. E-mail: jfuruse@ks.kyorin-u.ac.jp

Received August 29, 2012; accepted September 30, 2012

The Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG) was constituted in April 2008 to develop new standard treatments for hepatobiliary and pancreatic cancer. In pancreatic cancer, the Hepatobiliary and Pancreatic Oncology Group focuses on establishing standard chemotherapy or chemoradiotherapy for unresectable locally advanced disease. The JCOG 0506 study was a Phase II study of gemcitabine alone to examine its efficacy and safety in patients with locally advanced disease. The results in survival significantly exceeded expectations, and gemcitabine monotherapy has come to be regarded as the provisional standard therapy by our group. Following JCOG 0506, the JCOG 1106 study, which is currently under investigation, is a randomized Phase II study to evaluate the efficacy of induction chemotherapy with gemcitabine in combination with S-1 chemoradiotherapy and select a candidate therapeutic agent in a Phase III study comparing with gemcitabine alone. The JCOG 0805 study was a randomized Phase II study comparing S-1 monotherapy with gemcitabine plus S-1 combination therapy for unresectable biliary tract cancer. As a result, gemcitabine plus S-1 combination therapy was considered the more promising candidate in comparison with the gemcitabine plus cisplatin combination therapy in a subsequent Phase III trial. The Hepatobiliary and Pancreatic Oncology Group is planning a Phase III study to compare gemcitabine plus S-1 combination therapy with gemcitabine plus cisplatin combination therapy (JCOG PC1113 study). No standard postoperative adjuvant treatment has been established. We plan to conduct a Phase III study to compare S-1 as adjuvant therapy after surgery with surgery alone in patients with biliary tract cancer (JCOG PC1202).

Key words: GI-Hepatobiliary-Med – GI-Pancreas-Med – clinical trials

INTRODUCTION

Hepatobiliary and pancreatic cancers have a high incidence and are associated with high mortality rates, not only in Japan, but also around the world. Despite the poor prognosis, no standard chemotherapeutic regimens were established for these cancers for a long time.

In Japan, based on the results of single-arm Phase I and II studies (1–4), gemcitabine was approved for the treatment of pancreatic cancer in 2001, and for the treatment of biliary tract cancer in 2006. S-1, a mixture of tegafur, gimeracil and oteracil potassium, was also approved for the treatment of pancreatic cancer in 2006, and for the treatment of biliary

tract cancer in 2007. Furthermore, in a Phase III study conducted mainly in Europe, sorafenib showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) (5), and in 2009, this drug was approved for the treatment of HCC in Japan. Thus, some agents have shown beneficial effects and have come to be established as standard or available treatments for these cancers. Nonetheless, treatment remains unsatisfactory, and in order to improve the survival in patients with these cancers, not only more effective treatments for unresectable disease, but also more effective postoperative adjuvant therapy regimens for patients who undergo surgical resection need to be developed.

The Hepatobiliary and Pancreatic Oncology Group (HBPO group) of the Japan Clinical Oncology Group (JCOG) was constituted in April 2008 to develop new standard treatments for hepatobiliary and pancreatic cancer. The HBPO group started with a membership of 16 institutes initially, and at present, 26 institutes are registered as active members. Furthermore, >30 institutes participate in regular meetings of the JCOG.

HEPATOCELLULAR CARCINOMA

Various treatment modalities, including resection, local ablation, transcatheter arterial chemoembolization and liver transplantation have been employed as local therapeutic strategies for the treatment of HCC. Intra-arterial infusion chemotherapy and systemic chemotherapy have also been used for the treatment of advanced HCC. Thus, the treatments for HCC are diverse, and appropriate strategies are selected for each patient according to the tumor stage and the grade of liver dysfunction. Although hepatic arterial infusion chemotherapy, which is applied for patients with advanced-stage HCC such as those with portal vein tumor thrombosis and/or huge tumors, has provided high response rates, the survival benefit of this treatment modality in HCC patients has never been confirmed. No standard systemic chemotherapy had ever been established until sorafenib was approved.

Sorafenib is a small-molecule multi-kinase inhibitor that inhibits several kinases such as Raf kinase, vascular endothelial growth factor receptor and platelet-derived growth factor receptor- β tyrosine kinases. A large randomized controlled trial of sorafenib versus placebo (the SHARP trial) in patients with advanced HCC and good liver function (Child-Pugh class A) demonstrated that sorafenib prolonged the survival in patients with advanced HCC (5). As a result, sorafenib has been applied as standard chemotherapy for the treatment of advanced HCC in many countries, including Japan.

New compounds have been investigated for HCC in clinical trials, including Phase III trials, conducted by pharmaceutical companies in various study settings, such as first-line therapy in comparison with sorafenib, second-line therapy (placebo-controlled trial) and in combination with local treatments. To date, however, no compound has

yielded satisfactory results. Although sorafenib is the only antitumor drug that has shown survival benefit, the direct antitumor effect of the drug is not remarkable; the response rate has been reported to be only around 2–4%. Thus, there remains much room for improvement of the treatment efficacy and we think it is necessary to develop more effective treatment regimens containing sorafenib. The HBPO group is considering clinical trials using sorafenib to develop more effective treatments, e.g. combination of hepatic arterial infusion chemotherapy with sorafenib.

BILIARY TRACT CANCER

Bile duct cancer is subdivided according to the anatomic location of origin into intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer or ampulla of Vater cancer. Each of these types of cancer has characteristic features and the treatment strategies and prognoses differ. Furthermore, most patients present with obstructive jaundice at diagnosis, and biliary drainage is generally needed before any of the aforementioned treatments. These characteristics of biliary tract cancer have made it difficult to evaluate the efficacy of chemotherapy for biliary tract cancer, resulting in a paucity of high-quality clinical trials.

In Japan, gemcitabine and S-1 were approved for the treatment of biliary tract cancer in 2006 and 2007, respectively, based on the results of single-arm Phase II studies of the two drugs. Recently, a randomized Phase III study (ABC-02) comparing gemcitabine alone with gemcitabine plus cisplatin (GC) was conducted in the UK (6), which demonstrated a statistically significant improvement in the overall survival in the GC group when compared with that in the gemcitabine-alone group. The BT22 study was conducted to confirm the efficacy and safety of GC therapy as a company-initiated trial in Japan, and similar results to those of the ABC-02 study were demonstrated in Japanese patients with biliary tract cancer (7). Thus, GC therapy has come to be recognized as the standard chemotherapy for unresectable biliary tract cancer. Based on these results, treatment with cisplatin in combination with gemcitabine was approved for the treatment of biliary tract cancer in Japan in February 2012.

On the other hand, S-1 or gemcitabine plus S-1 (GS therapy) was demonstrated to provide high response rates and good survival rates in Phase II studies (4,8), and S-1 or GS therapy was expected to yield a superior benefit to GC therapy. Therefore, the HBPO group conducted a randomized Phase II study comparing S-1 monotherapy with GS therapy (JCOG 0805 study) to examine the efficacy and safety of the two regimens and to select the more promising one for a subsequent Phase III trial of treatment for unresectable biliary tract cancer in (Fig. 1) (9,10). The main eligibility criteria of the JCOG 0805 study were the following: (i) clinically diagnosed with biliary tract cancer, which includes intrahepatic cholangiocarcinoma, extrahepatic




Figure 1. Study design of the JCOG 0805 study.




Figure 2. Study design of the JCOG PC1113 study.

cholangiocarcinoma, gallbladder cancer and ampulla of Vater cancer and histologically proven adenocarcinoma or adenosquamous carcinoma; (ii) recurrent or unresectable biliary tract cancer; (iii) no previous therapy against biliary tract cancer except surgery; (iv) no previous chemotherapy or radiotherapy for any other malignancies; (v) ECOG performance status of 0 or 1 and (vi) adequate organ function. The regimen that shows the higher point estimate in terms of the proportion of 1-year survival will be considered to be more promising. We assumed that the 1-year survival rate of one regimen is 30% and that of the other regimen is >40%. In this situation, the sample size ensuring at least 85% probability of correct selection of the more effective regimen is 98 patients, with 49 patients in each of the two arms. Considering the likelihood of some ineligible patients being enrolled, the total number of patients was set at 100 (9).

In the JCOG 0805 study, 101 patients were enrolled between February 2009 and April 2010, with 51 allocated to the GS arm and 50 to the S-1 arm. The 1-year survival rates were 52.9 and 40.0%, the median overall survival rates were

12.5 and 9.0 months [hazard ratio 0.86; 95% confidence interval (CI): 0.54–1.36; $P = 0.52$] and the median progression-free survival rates were 7.1 and 4.2 months (hazard ratio 0.44; 95% CI: 0.29–0.67; $P < 0.0001$), respectively, in the GS arm and S-1 arm. The most common toxicities were hematological toxicities, fatigue and rash. Grade 3 or 4 toxicities were generally more frequent in the GS arm than that in the S-1 arm, although both treatments were quite well tolerated. As a result, GS therapy was considered as the more promising candidate in comparison with the GC regimen in a subsequent Phase III trial (10). The HBOP is planning a Phase III study to compare GS therapy with GC therapy (JCOG PC1113 study), with the aim of determining whether GS therapy could be established as a new standard therapy for unresectable biliary tract cancer (Fig. 2).

Although surgery currently remains the only potentially curative treatment, most patients develop recurrence. An effective adjuvant therapy is required after surgery to increase the curability of the surgery and to prolong the survival in patients with biliary tract cancer who undergo surgery. To

date, since no large randomized controlled trials of adjuvant therapy have been conducted, no standard postoperative adjuvant treatment has been established. We consider S-1 as a potential candidate for adjuvant therapy, because a high response rate of 35% was demonstrated to S-1 in a Phase II study for unresectable biliary tract cancer (4). S-1 has also been already established as a standard adjuvant therapeutic agent for the treatment of gastric cancer. Surgical methods for the treatment of biliary tract cancer are highly diverse, including pancreaticoduodenectomy, hepatectomy, etc., when compared with those for gastric cancer. Therefore, a feasibility study of S-1 chemotherapy after surgery was conducted by a study group comprising some member institutes of the HBPO group. A treatment completion rate of 82% was achieved. The most common grade-3 toxicity was neutropenia (18%), and the rates of other grade 3 adverse events were under 5% (11). Therefore, S-1 is considered to be suitable as a postoperative adjuvant therapeutic agent for the treatment of patients with resected biliary tract cancer. Based on these results, we plan to conduct a Phase III study to compare S-1 as adjuvant therapy after surgery with surgery alone in patients with biliary tract cancer (JCOG PC1202).

PANCREATIC CANCER

Pancreatic carcinoma is a disease with one of the worst prognoses; the 5-year survival rate of patients diagnosed as having pancreatic cancer remains at 5–10%. Since it is difficult to diagnose pancreatic cancer at an early stage, 70–80% patients with pancreatic cancer have unresectable disease, including locally advanced or distant metastatic disease, at diagnosis. Since gemcitabine demonstrated a better survival benefit when compared with 5-fluorouracil (5-FU) in a Phase III study (12), it has been widely used as the standard chemotherapy for unresectable pancreatic cancer for >10 years. Despite a number of new compounds, including molecular-targeted agents, having been examined in combination with gemcitabine, no regimen, except for gemcitabine plus erlotinib, has been demonstrated to provide statistically significant improvement in

the overall survival over gemcitabine alone (13,14). Thus, the prognosis of these patients with this cancer remains poor, and the development of more effective treatments for pancreatic cancer is urgently needed.

Under these situations, it is important to continue the development of new compounds in industry-initiated clinical trials and also participate in global registration trials. On the other hand, the HBPO group also considers itself as having the important role of establishing standard chemotherapy or chemoradiotherapy for unresectable locally advanced disease or postoperative adjuvant therapy.

With regard to treatments for unresectable locally advanced disease, we first conducted a Phase II study of gemcitabine alone to examine its efficacy and safety in patients with locally advanced disease of the JCOG 0506 study (15). This study was conducted to be foreseeing a Phase III trial comparing gemcitabine monotherapy with conventional chemoradiotherapy using 5-FU, which, at that time, was used as a standard therapy for locally advanced disease. The main eligibility criteria of the JCOG 0506 study were the following: (i) patients with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma; (ii) International Union Against Cancer clinical stage III (T4N0-1 and M0); (iii) no previous chemotherapy or radiotherapy for any other malignancies; (iv) ECOG performance status of 0, 1 or 2 and (v) adequate organ function. The primary endpoint of this study was the 1-year survival rate. A sample size of 50 was required for a one-sided α of 0.20 and β of 0.10, with an expected 1-year survival rate of 40% and a threshold 1-year survival rate of 25%. Fifty patients were enrolled from January 2006 to February 2007 in this study. The results revealed a median overall survival of 15.0 months with a 1-year survival rate of 64.0% (Table 1), which significantly exceeded expectations. The toxicities were generally mild and the drug was well tolerated. Furthermore, a randomized controlled trial of gemcitabine vs. conventional chemoradiotherapy using 5-FU and cisplatin failed to show any survival benefit of chemoradiotherapy (16). Based on these results, gemcitabine monotherapy has come to be regarded as the provisional standard therapy by our group (Table 2).

Table 1. Recent randomized controlled trials using gemcitabine, cisplatin and/or S-1 for unresectable biliary tract cancer

Study	Chemotherapy	n	Response rate (%)	Median PFS (months)	Median OS (months)	Study
ABC-02 study	Gemcitabine	206	15.5	5.0	8.1	Valle <i>et al.</i> (6)
	Gemcitabine + cisplatin	204	26.1	8.0	11.7	
BT-22 study	Gemcitabine	42	11.9	3.7	7.7	Okusaka <i>et al.</i> (7)
	Gemcitabine + cisplatin	41	19.5	5.8	11.2	
JCOG 0805 study	S-1	50	17.4	4.2	9.0	Ueno <i>et al.</i> (8)
	Gemcitabine + S-1	51	36.4	7.1	12.5	


PFS, progression-free survival; OS, overall survival.

Downloaded from <http://jco.oxfordjournals.org/> at National Cancer Centre (JMMLA) on February 18, 2013

Table 2. Recent clinical trials of chemotherapy or chemoradiotherapy for locally advanced pancreatic cancer

Study	Radiotherapy (Gy)	Chemotherapy	n	Median OS (month)	%1-year survival	Study
JCOG 0506 study	–	Gemcitabine	50	15.0	64	Ishii <i>et al.</i> (15)
S-1 radiation Phase II study	50.4	S-1	61	16.2	72	Ikeda <i>et al.</i> (18)
2000-01 FFCD/SFRO study	60	5-fluorouracil + cisplatin	59	8.6	32	Chauffert <i>et al.</i> (16)
ECOG 4201 study	–	Gemcitabine	60	13.0	53	Lochner <i>et al.</i> (17)
	50.4	Gemcitabine	34	11.1	50	
	–	Gemcitabine	37	9.2	32	

%1-year survival, one-year survival rate.



Gemcitabine: 1000 mg/m² d1, 8, 15, repeated every 4 weeks
S-1: 80 mg/m²/day on the day of irradiation

Figure 3. Study design of the JCOG 1106 study.

A clinical trial conducted in the USA comparing gemcitabine plus radiotherapy vs. gemcitabine alone reported that the overall survival rate was superior in the combined treatment group when compared with that in the gemcitabine-alone group in patients with locally advanced pancreatic cancer (17). Furthermore, chemoradiotherapy using S-1 demonstrated promising efficacy in a Phase II study, which was conducted as an in-house trial of some member institutes of the HBPO group; the median overall survival was 16.2 months (18). There is a possibility that new methods of chemoradiotherapy might improve the survival, especially prolonged survival of >2 years. Thus, in order to develop more promising new chemoradiotherapies, we conducted a randomized Phase II study of two chemoradiotherapeutic methods, one consisting of S-1 chemoradiotherapy and maintenance therapy with gemcitabine, and the other consisting of induction gemcitabine chemotherapy for 3 months followed by S-1 chemoradiotherapy and maintenance therapy with gemcitabine (JCOG 1106 study).

The JCOG 1106 study is a multi-institutional open-label randomized Phase II study to evaluate the efficacy of induction chemotherapy of gemcitabine in combination with S-1 chemoradiotherapy and select a candidate in a Phase III study comparing with gemcitabine alone (Fig. 3). The main eligibility criteria of the JCOG 1106 study were as follows: (i) clinically diagnosed with pancreatic cancer without distant metastasis, and histologically proven adenocarcinoma; (ii) no previous chemotherapy or radiotherapy for any other malignancies; (iii) ECOG performance status of 0 or 1 and (iv) adequate organ function. The primary endpoint is the overall survival, and we shall select the treatment method providing the better survival benefit between the two for use in a subsequent Phase III study. The 1-year survival rate of the two treatments would be expected to be >60% at least, because that of patients administered gemcitabine monotherapy was 64% in the JCOG 0506 study. The sample size is 100 patients and this study is under investigation in September 2012.

FUTURE DIRECTION

In hepatobiliary tract and pancreatic cancers, major advances have been made in relation to the establishment of standard treatments in recent years. However, the survival of patients with these cancers still remains dismal. The HBPO group considers it essential to actively conduct clinical trials to establish more effective standard treatments, including a combination of chemotherapy with local treatments including surgery or radiotherapy.

In HCC, many clinical trials using new agents are conducted as an Asian study including Japan or a global study. However, it is difficult to conduct investigator-initiated trials in HCC, because there are various differences in the etiology and treatment strategy among Asian countries, Japan and Western countries. However, it is also important for the HBPO group to discuss Asian studies on HCC and biliary tract cancer in the future, because these diseases are very common in Asia, compared with Western countries.

Establishment of standard therapies for relatively rare tumors is urgently needed. We are planning to conduct a

phase III study for the treatment of gastrointestinal neuroendocrine tumors in cooperation with other groups of the JCOG.

Although our HBPO group is growing in size, only 26 institutes are active members of the group. On the other hand, >30 institutes participate in our regular meetings as observers. It is therefore also important to increase the number of institutes as active members so as to make it possible to conduct larger clinical trials of higher quality in the future.

Funding

The clinical trials of JCOG described in this paper were mainly supported by the research aid from Ministry of Health, Labour, and Welfare of Japan.

Conflict of interest statement

None declared.

References

1. Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. *Jpn J Clin Oncol* 2001;31:7–12.
2. Okusaka T, Ishii H, Funakoshi A, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. *Cancer Chemother Pharmacol* 2006;57:647–53.
3. Okusaka T, Funakoshi A, Furuse J, et al. A late phase II study of S-1 for metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 2008;61:615–21.
4. Furuse J, Okusaka T, Boku N, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. *Cancer Chemother Pharmacol* 2008;62:849–55.
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359:378–90.

6. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010;362:1273–81.
7. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. *Br J Cancer* 2010;103:469–74.
8. Sasaki T, Isayama H, Nakai Y, et al. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. *Cancer Chemother Pharmacol* 2010;65:1101–7.
9. Takashima A, Morizane C, Ishii H, et al. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). *Jpn J Clin Oncol* 2010;40:1189–91.
10. Ueno M, Okusaka T, Mizusawa J, et al. Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: results of the Japan Clinical Oncology Group study (JCOG0805). *J Clin Oncol* 2012;30 (Suppl; abstr 4031).
11. Konishi M. Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. *J Hepatobiliary Pancreat Sci* 2012;19:301–5.
12. Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997;15:2403–13.
13. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007;25:1960–6.
14. Hidalgo M. Pancreatic cancer. *N Engl J Med* 2010;362:1605–17.
15. Ishii H, Furuse J, Boku N, et al. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. *Jpn J Clin Oncol* 2010;40:573–9.
16. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. *Ann Oncol* 2008;19:1592–9.
17. Lochrer PJ, Jr, Feng Y, Cardenas H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. *J Clin Oncol* 2011;29:4105–12.
18. Ikeda M, Ioka T, Ito Y, et al. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2012 [Epub ahead of print].

Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial)

Takuji Okusaka · Makoto Ueno · Tosiya Sato · Yuji Heike

Published online: 25 January 2012

© Japanese Society of Hepato-Biliary-Pancreatic Surgery and Springer 2012

Abstract

Background/purpose In biliary tract cancer, few clinical studies evaluating immunotherapy have been reported. A phase I and randomized phase II study with Wilms tumor 1 (WT1) peptide vaccine plus gemcitabine and cisplatin (GC) for chemo-naïve patients with unresectable or recurrent biliary tract cancer was started, because the overexpression of WT1 is seen in the majority of patients with this disease, encouraging the potential of WT1-based immunotherapy. This trial was registered at the UMIN Clinical Trials Registry as UMIN 000004886.

Methods and results The aim of this trial is to evaluate the efficacy and safety of the regimen and to determine whether the regimen should be compared with the current standard regimen, GC, in a subsequent phase III trial for patients with unresectable or recurrent biliary tract cancer. Six patients in the phase I study and a total of 100 patients in the phase II study will be accrued over a 2-year period.

The patients in the phase II study will be randomized at a 2:1 ratio to receive GC either with or without WT1 peptide vaccine. The primary endpoint of the phase II study is the 1-year overall survival rate.

Conclusions This is the first randomized trial to evaluate the use of immunotherapy in patients with advanced biliary tract cancer.

Keywords Biliary tract cancer · Immunotherapy · Chemotherapy · Wilms tumor 1 (WT1) peptide vaccine · Randomized trial

Introduction

Systemic chemotherapy is usually indicated for patients with unresectable advanced biliary tract cancer or for those who have relapsed after operation; however, no standard treatments with solid evidence of a survival benefit have been established for such patients [1]. Although gemcitabine (GEM) alone was regarded as the de-facto standard regimen for advanced biliary cancer until recently, gemcitabine plus cisplatin (GC) has become the new standard regimen, based on the results of the ABC-02 trial [2], which showed a significant survival advantage for the GC combination over GEM alone. Even with the establishment of a standard therapy for this disease, the prognosis of these patients remains dismal: their median survival period is only around 10 months [2, 3]. Therefore, a clear need exists for new, effective, treatments for the management of biliary tract cancer (Fig. 1).

Recent progress in understanding the basic aspects of immunology has led to the development of immune-based therapies for various types of cancers. The identification of


T. Okusaka (✉)
Hepatobiliary and Pancreatic Oncology Division,
National Cancer Center Hospital, 5-1-1 Tsukiji,
Chuo-ku, Tokyo 104-0045, Japan
e-mail: tokusaka@ncc.go.jp

M. Ueno
Division of Hepatobiliary and Pancreatic Medical Oncology,
Kanagawa Cancer Center, Yokohama, Japan

T. Sato
Department of Biostatistics, Kyoto University
School of Public Health, Kyoto, Japan

Y. Heike
Department of Medical Oncology,
National Cancer Center Hospital, Tokyo, Japan

Fig. 1 Study design. *DLT* dose-limiting toxicity, *CDDP* cisplatin, *WT 1* Wilms tumor 1



various cancer antigens has facilitated many clinical trials of cancer vaccines that are expected to become new treatment strategies. Recently, sipuleucel-T immunotherapy for metastatic, asymptomatic hormone-refractory prostate cancer [4] and immunotherapy with ipilimumab for metastatic melanoma [5] have produced statistically significant improvements in survival, and both of these treatments have been approved by the United States Food and Drug Administration. Sipuleucel-T stimulates T-cell immunity against prostatic acid phosphatase, and ipilimumab blocks the potentiation of cytotoxic T-lymphocyte-associated antigen 4 and the antitumor T-cell response. Unfortunately, few preclinical studies examining biliary tract cancer have shown promising immune responses similar to those induced by sipuleucel-T against prostate cancer or those induced by

ipilimumab against melanoma, and few clinical studies of immunotherapy for biliary tract cancer have been reported because of the rarity of this disease and the poor physical conditions of most patients at the time of the initial diagnosis. However, GEM has been reported not to suppress immunological cells, but to increase the population of dendritic cells that serve as antigen-presenting cells [6, 7]. Therefore, we conducted a phase I trial of Wilms tumor 1 (WT1) peptide vaccine and GEM combination therapy in patients with advanced pancreatic or biliary tract cancer [8]. Although the aim of that study was to assess the safety of the combination of WT1 peptide vaccine and GEM in a small population, it also showed that the WT1 peptide vaccine was safe enough to be employed in patients with advanced pancreatic or biliary tract cancer in combination with GEM, and